AzTrials
AzTrials

Sensorineural Hearing LossEarly Phase 1NCT06025097

Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.

A Early Phase 1 study testing Combination Solution in people with Sensorineural Hearing Loss and Tinnitus, run by Combined Military Hospital Rawalpindi at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Steroids are used widely for the treatment of Sensorineural hearing loss worldwide. The difficulty lies with efficient delivery of the drug into the cochlea, which is already a sealed chamber with limited blood supply that too with an end Artery. Read more about this study

Who is it for?
Ages 10 to 70 years
Conditions the study is for
Sensorineural Hearing Loss, Tinnitus
What is being tested?
Combination Solution
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 sitePakistan
Study dates
1 Sep 2023to 21 Oct 2023
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 to 70 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Age: 10-70 yrs
  • Capacity to have a Pure tone Audiometry test
  • Disease
  • SNHL;
  • Unilateral or bilateral sensorineural hearing loss
  • Without any identifiable cause
Show all 10Show fewer
  • Tinnitus;
  • Subjective sensation of noise without any obvious source of sound
  • Without any identifiable cause
  • Hearing levels of 55dB or above

Who cannot join

  • Age: less than 10 or more than 70 yrs
  • Conductive hearing loss/ Mixed Hearing loss
  • Tumor, Neurologic cause of hearing loss/ tinnitus
  • Past ear Surgery
  • Any External, middle or inner Ear Disease other than SSNHL
  • Traumatic Hearing Loss or Hearing Loss due to an obvious cause.
Show all 16Show fewer
  • Patients' refusal to follow-up
  • Any contraindication to Steroids administration.
  • Any Blood Disorder
  • Non-consenting patients
  • Comorbid:
  • Diabetes
  • Hypertension
  • Cardio vascular diseases
  • Obesity
  • Etc.

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • Combined Military Hospital

    Rawalpindi, Punjab Province, 75700

Other trials in Pakistan

About this study

Official title: Therapeutic Effect of Intra-Tympanic Methyl Prednisone-platelet Rich Plasma Combination in Sensorineural Hearing Loss and Tinnitus of Cochlear Origin.

Steroids are used widely for the treatment of Sensorineural hearing loss worldwide. The difficulty lies with efficient delivery of the drug into the cochlea, which is already a sealed chamber with limited blood supply that too with an end Artery. We intend to extrapolate its effects by combining it with Platelet rich plasma. intra-tympanic delivery is achieved with injection via tympanic membrane and its absorption via round window is hastened by posture maintenance for about half an hour. PRP is an autologous biologic fluid which has excellent safety profile and is already in use by various specialties.

Read the detailed description

Definitions:

Sensorineural Hearing Loss: Hearing loss occurring due to pathologies of cochlea.

Platelet-rich plasma : Platelet-rich plasma is an autologous biological product separated from blood after removal of Red blood cells. It is the plasma portion of blood which is simply rich of platelets.

Preparations:

Intratympanic methyl prednisone + Autologous PRP: 2ml Solution (1ml of methyl prednisone 40mg/ml + 1ml of PRP)

Materials and Methods:

Inclusion Criteria:

mentioned in pertinent section

Exclusion Criteria:

mentioned in pertinent section

Methodology:

This will be an Interventional study, prior permission from Hospitals Ethical Review Board will be taken. Informed consent will be obtained from the patients with regards to participation the study. All the patients in which the presentation to Ear Nose Throat (ENT) clinic is SNHL or Subjective tinnitus and also satisfying the inclusion criteria will be selected. SNHL will be graded according to the audiogram and values will be recorded to the nearest +5db with round off. The Tinnitus will be graded on visual analogue scale graded from 1 to 10 (1= No tinnitus while 10 being the worst). After recording the pre-treatment data these patients will be scheduled for intervention. Patients will receive the solution consisting of 1ml methyl prednisone (40mg/ml) and 1ml of PRP via intra-tympanic route. The solution will be injected into the tympanic cavity via the tympanic membrane injection (intra-tympanic route). Patients will receive repeated doses of same intra-tympanic injections on every third day for a total of 3 consecutive doses (in 9 days). Hearing assessment via Audiometry will be done post-treatment after 2 weeks of finishing the treatment (23rd day after starting the therapy).

Procedure: On receiving a patient at ENT department with a diagnosis of SNHL/ tinnitus, patient will be scheduled for intra-tympanic injection session. All of the intra-tympanic injections will be performed by the same ENT Doctor. Patient will be positioned in sitting posture, head tilted sideways and rotated slightly to instill the pyodine solution into the ear for 5 minutes. Then after cleaning with a sterile suction tip, xylocaine 10% solution will be sprayed into the ear canal and a wick soaked in xylocaine left there for 5 more minutes. The wick will then be removed and ear will be examined to exclude any physical disease or deformity in the external ear. Head will be brought to the examining position and a sterile 3cc syringe will be loaded with 1 ml of 40mg/ml methyl prednisone and 1 ml of PRP. 3cc syringe needle is replaced with 25 Guage Lumber Puncture needle. Under guidance of a Microscope or 0-degree rigid Endoscope, one point Pin-hole will be made by just piercing the Tympanic membrane antero-inferiorly and the prepared solution will be instilled. While instilling the solution a meniscus would be seen rising from inferior to superior aspect of the tympanic membrane. The patient will be made to lie in supine position and then will be made to stay in same position for about 15-30 mins (so as to hasten the absorption through round window and to prevent escape of solution via Eustachian tube). This supine position would also facilitate establishment of a reservoir in the mastoid antrum to slowly discharge over time and further the absorption through round window. A cotton wick will be left in the ear canal to be removed after an hour. The procedure will be repeated at every 3rd day till a total of three procedures. Patient will be further called for follow up Audiometry, at 2 weeks after finishing the treatment. Any improvement from the pre-treatment audiometry will be noted. Improvement will be labelled as Mild; of 10 decibels, partial; 11-25 decibels and Good; above 25 decibels. The improvements in tinnitus will be ascertained subjectively with a visual analogue scale graded from 1 to 10. Data will be recorded and analyzed and results will be published in due course of time.

Being tested
Combination Solution
Keywords
Steroids, Platelet rich plasma, intratympanic steroids
Medical subject headings
Hearing Loss, Sensorineural, Tinnitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Combination SolutionDrug

    Also called PRP + Solumedrol

    Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.

Study groups in NCT06025097
Study groupRoleWhat they receive
Single Treated ArmExperimentalSingle arm study, Patients with SNHL and Tinnitus all were given same Composite solution consisting of (Methyl prednisone and Platelet rich plasma) via intr-atympanic route..
Receives: Drug: Combination Solution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improvement in Hearing

    Improvement in hearing as per Audiogram, measured in decibels.

    Measured: 2 weeks post treatment completion.

  2. Improvement in Tinnitus

    Improvement in Tinnitus as per Visual analogue scale from 1 to 10 with 1 being the lowest improvement and 10 being the best.

    Measured: 2 weeks post treatment completion.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Sep 2023
  2. Study start1 Sep 2023
  3. Primary completion30 Sep 2023
  4. Study completion21 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Single group study, to show the therapeutic effects of Combination solution on diseases in fixed time.
Masking
None (open label)
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06025097
Sponsor's protocol ID
001
Status last verified
Feb 2024
First submitted
10 Aug 2023
Last updated
22 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: If there is a need to analyze the data for a particular clinical question, than only the data would be shared with other researchers.

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Combination Solution in people with Sensorineural Hearing Loss and Tinnitus, run by Combined Military Hospital Rawalpindi at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improvement in Hearing (time frame: 2 weeks post treatment completion.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in